Cas:14155-23-8 METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE manufacturer & supplier

Chemical Name:METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE

CAS.NO:14155-23-8

Synonyms:2-Phenyl-6-methoxybenzothiazol;Benzothiazole,6-methoxy-2-phenyl;6-Methoxy-2-phenyl-benzothiazol;6-methoxy-2-phenylbenzothiazole

Molecular Formula:C₁₄H₁₈O₆

Molecular Weight:282.28900

HS Code:2932999099

Physical and Chemical Properties:

Melting point:198-200ºC

Boiling point:473ºC at 760 mmHg

Density:1.36g/cm3

Index of Refraction:1.586

PSA:77.38000

Exact Mass:282.11000

LogP:0.19370

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Phenyl-6-methoxybenzothiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-methoxy-2-phenylbenzothiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzothiazole,6-methoxy-2-phenyl Use and application,6-methoxy-2-phenylbenzothiazole technical grade,usp/ep/jp grade.

Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE manufacturer Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined. METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE supplier ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE vendor The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. METHYL 4,6-O-BENZYLIDENE-β-D-GLUCOPYRANOSIDE factory Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).